Back to Search
Start Over
Risk factors for progression to acute respiratory failure after casirivimab and imdevimab administration: A retrospective study
- Source :
- Respiratory Investigation; 20220101, Issue: Preprints
- Publication Year :
- 2022
-
Abstract
- Casirivimab and imdevimab are effective in preventing hospitalization in outpatients with coronavirus disease 2019 (COVID-19); however, disease progression after casirivimab and imdevimab administration has been reported. This study aimed to elucidate the risk factors for disease progression after casirivimab and imdevimab administration.
Details
- Language :
- English
- ISSN :
- 22125345
- Issue :
- Preprints
- Database :
- Supplemental Index
- Journal :
- Respiratory Investigation
- Publication Type :
- Periodical
- Accession number :
- ejs59618698
- Full Text :
- https://doi.org/10.1016/j.resinv.2022.04.005